7 stories
Regulation as a tag covers the broader policy and rule-making picture across the peptide field — beyond just the FDA. This is where the international pieces, state-level moves, and cross-cutting policy stories land.
Active threads in 2025 and 2026: UK MHRA enforcement on research peptides, Australian TGA action on compounding, Health Canada warnings, Indian CDSCO oversight after the semaglutide patent expired, and EMA reviews of GLP-1 safety signals. State-level legislation on telehealth GLP-1 access has produced its own thread, particularly in states with strong consumer-protection mandates.
For FDA-specific stories see #fda; for compounding-specific policy see #compounding and #peptide-policy. This tag covers the broader landscape.
Scientific American reports that the FDA's decision to convene an expert advisory panel — rather than unilaterally reclassifying peptides — signals a more cautious approach than RFK Jr.'s original February pledge suggested. The panel will weigh limited safety data against surging consumer demand and a growing black market for unregulated peptide products.
India's drug regulators are intensifying GLP-1 oversight ahead of semaglutide's patent expiry. The Drug Controller General audited 49 entities and issued notices to violators.
Hims & Hers stock briefly rallied on reports the FDA may ease peptide restrictions, but gains reversed. The company had proactively acquired a peptide production facility in California in 2025.
India's Central Drugs Standard Control Organization issued advisories against unsupervised use of semaglutide and tirzepatide for weight loss, cracking down on misleading social media promotions and unapproved compounded versions.
Federal regulators are moving toward restoring legal access to injectable peptides barred from pharmacy compounding in 2023, which could redirect patients from unregulated online sellers to regulated pharmacy channels.
The FDA is evaluating potential changes to dietary supplement warning label requirements, with pharmacists urged to remain vigilant as regulations may loosen under the current administration.
Investigation into the unregulated peptide market noting how easily BPC-157 can be purchased online with next-day delivery, amid celebrity endorsements from Joe Rogan and growing safety concerns.